Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
XXXXXXX
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx se mění x xxxxxxxx sdělení Xxxxxxxxxxxx zahraničních xxxx x. 58/2007 Sb. x. s., č. 46/2008 Sb. m. x. x x. 47/2012 Xx. m. x. o Xxxxxxxxxxx xxxxxx xxxxx dopingu xx sportu
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, že dne 16. xxxxxxxxx 2011 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Mezinárodní úmluvy xxxxx xxxxxxx xx xxxxxx.1)
X xxxxx xxxxxx Xxxxxxx I xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky.
Nové xxxxx Přílohy X xxxxxxxxx v xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx dne 1. xxxxx 2012 x xxxxx dnem xxxxxxxxx x platnost x pro Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx znění Přílohy X x platnost xxxxxxxx xxxxxx xxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx xxxxxx xx 1. ledna 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx českého xxxxxx xx xxxxxxxxx xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxxx xxx 19. xxxxx 2005 v Paříži xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s.
MEZINÁRODNÍ XXXXXX XXXXX XXXXXXX XX SPORTU
Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Mezinárodní xxxxxxxx
Xxxxx, 1. xxxxx 2012
XXXXXX XXXXXXXXXX XXXXX X XXXXX DOPINGU XXX XXX 2012
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. ledna 2012
Xxxxx článku 4.2.2 Xxxxxxxxx antidopingového xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx považovány xx "Xxxxxxxxxx látky" xxxxx látek ze xxxxxx S1, X2, X4.4, X4.5 x X6(x) x Xxxxxxxxxx xxxxx M1, X2 x M3.
XXXXX X METODY XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX) |
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx sekcích Seznamu x není xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (např. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxx xxxx xx ukončené xxxxxxxxxx, syntetické xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
S1. XXXXXXXXXX LÁTKY
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (AAS):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolon; xxxxxxxxxxx; metasteron (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-dion); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.
(b) Xxxxxxxxx** AAS, xxxxx xxxx xxxxxx exogenně:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), androstendion (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, prasteron (xxxxxxxxxxxxxxxxxxxxx, DHEA), testosteron x jejich metabolity x isomery, xxx xx s xxxxxxxx xxxxx xx xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-androstan-3β,17β-diol | xxxxxxxxxxxxxx |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-xxxxxxx-5αxxxxxxxxx-17-xx |
androst-4-en-3α,17β-diol | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
androst-5-en-3β,17α-diol | 7α-hydroxy-DHEA |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-hydroxy-DHEA |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
xxxxxxx-5-xx-3β,17α-xxxx | 19-xxxxxxxxxxxxxx |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-xxxxxxxxxxxxxxxxx |
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, zilpaterol, xxx xx x omezením xxxxx na xx.
Xxx účely xxxxxxx xxxx sekce: * "xxxxxxxx" se vztahuje x látce, kterou xxxx xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx xxxxxxxxxx xxxxxxxxx. |
X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ FAKTORY X PŘÍBUZNÉ XXXXX
Xxxxxxxxxxx látky x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (xXXX), stabilizátory xxxxxxx vyvolávajícího xxxxxxx (XXX), methoxypolyethylenglykol-epoetin beta (XXXX), xxxxxxxxxxx /Hematide/);
2. Choriogonadotropin (XX) x Iuteinizační xxxxxx (XX) x xxxx;
3. Xxxxxxxx;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx faktor-1 (IGF-1), xxxxxxxxxx růstové xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx jako xxxxxxxxx xxxx xxxxxxx xxxxxxx ovlivňující xxxxxxx xxxx xxxxxxxxx bílkovin xxxxx, šlach a xxxxxx, krevní zásobení, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx ovlivňující xxxx svalových xxxxxx;
x další látky x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
X3. XXXX2- AGONISTÉ
Všichni xxxx-2 agonisté (včetně xxxx xxxxxxxxxx optických xxxxxxx) jsou xxxxxxxx xxxxx xxxxxxxxxxx (maximálně 1600 xxxxxxxxxx za 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx xxxxxx x xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx výrobce.
Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 1000 ng/ml x xxxxxxxxxx formoterolu x xxxx x xxxxxxxxxxx xxxxx xxx 30 ng/ml nebude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, ale xxxx považována za xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx inhalační xxxxx xxxxx než xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.
2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxx xx x omezením xxxxx xx xx.
3. Xxxxxxx antiestrogenní látky xxxxxxxxxx:
Cyklofenil, xxxxxxxxxxx, xxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.
4. Xxxxx xxxxxxxxxxxx funkce xxxxxxxxxx včetně inhibitorů xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Proliferator Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx proteinkinasové xxx xxxxxxxxxx XXX x součinnosti s XXXX delta /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx agonists/ (xxxx. XXXXX)
X5. XXXXXXXXX X OSTATNÍ XXXXXXXXX XXXXX
Xxxxxxxxx látky xxxx zakázané. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, plasmaexpandery (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx a xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxxx xxxxxxxxxxxx účinky. Lokální xxxxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, kyselina etakrynová, xxxxxxxxx, xxxxxxxxxxxxx, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx x xxxxxxxxx xxxxxx dorzolamidu x xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Soutěž) jakéhokoliv xxxxxxxx xxxxx xx xxxxxxxxxx prahovým xxxxxxx (xx. formoterol, salbutamol, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx xx xxxxxxxxxx udělení xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx látku navíc x té, xxxxx xxx byla xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXX XXXXXXX XXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Krevní xxxxxx, xxxxxx použití xxxxxxxxx, xxxxxxxxx xxxx heterologní xxxx xxxx červených xxxxxxx x jim xxxxxxxxx produktů jakéhokoliv xxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx modifikované hemoglobinové xxxxxxxx (xxxx.xxxxxx náhražky xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (RSR13), xxx xx x xxxxxxxx pouze na xx. Xxxxxxxx kyslíku xxxxxxxx xxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx xxxxx o xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Dopingové xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx xxxxxx (např. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx pouze xx ně.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx 50 ml za 6 hodin xxxx xxxxxxxx kromě infuzí xxxxxxxxx přijatých x xxxxxxx nemocničních xxxxxxx xxxx klinických vyšetřovacích xxxxx.
3. Postupný xxxxx, xxxxxxxxxx a xxxxxxxxx xxxxxxxxxxx množství xxxx krve xx xxxxxxxxx xxxxxxx xx xxxxxxxx.
X3. GENOVÝ XXXXXX
X důvodu xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Použití xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx;
XXXXX X XXXXXX ZAKÁZANÉ XXX XXXXXXX |
Xxxxx xxxxxxxxx XX xx X5 x X1 xx X3 xxxxxxxxx xxxx xxxx Xxx Soutěži xxxxxxxx x následující xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx stimulancia (xxxxxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx, x xxxxxxxx derivátů imidazoiu x xxxxxxx jejich xxxxxxxx xxxxxxx x xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx pro xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Nespecifická xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, amfetamin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamin, xxxxxxxxxxx, xxxxxxxxxxx, fentermin, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, klobenzorex, xxxxxx, kropropamid, xxxxxxxxxx, xxxxxxxxx, mefentermin, metamfetamin (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, norfenfluramin, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx v xxxxx xxxxxxxx, je Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx**, katin***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, heptaminol, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, xxxxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, strychnin, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Následující xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2012 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx, synefrin) xxxxxx považovány xx Xxxxxxxx látky.
** Xxxxxxx xxxxxx xxxxxxxxxx (xxxx. xxxxx, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx není xxxxxxxx.
*** Xxxxx xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 ml xxxx.
**** Xxxxxxx x methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx moči.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx jeho xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx mililitr
X7. XXXXXXXXX
Zakázané xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), fentanyl x jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, morfin, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
X8. KANABINOIDY
Xxxxxxxx (xxxx. xxxxx, xxxxxx a xxxxxxxxx) xxxx syntetický delta9tetrahydrokanabinol (XXX) a xxxxxxxxxxxxxx (xxxx. "Xxxxx" /xxxxxxxxxx XXX018, JWH073/ x XX-210) jsou xxxxxxxx.
X9. GLUKOKORTIKOSTEROIDY
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, nitrožilní nebo xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX |
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx zakázaný xxxxx Xxx Soutěži v xxxxxxxxxxxxx sportech. Detekce xx bude provádět xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (hematologická xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Motocyklový xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. BETA-BLOKÁTORY
Xxxxx xxxx jinak xxxxxx, xxxx-xxxxxxxxx xxxx zakázány xxxxx Při Xxxxxxx x následujících xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Billiard (xxxxxxx xxxxxxxxxx) (WCBS)
∙ Bridž (FMB)
∙ Xxxx (XXX)
∙ Xxxxxxx a xxxxxxx (XXX)
∙ Xxxxxxx sporty a xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (FITA, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx,x snowboard U-rampa x "xxx air"
∙ Petanque x xxxxxxx sporty (CMSB)
∙ Xxxxxxx (ISSF, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, betaxolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx ne s xxxxxxxx pouze xx xx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 97/2012 Sb. x. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx xxxxxxx č. 97/2012 Sb. x. x. xxx xxxxxx xxxxxxx předpisem č. 98/2013 Sb. m. s. x účinností xx 20.12.2013.
Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx.